Gordon A Ferns1, Milad Shahini Shams Abadi2,3, Ahmad Raeisi4, Mohammad-Hassan Arjmand3,5. 1. Division of Medical Education, Brighton & Sussex Medical School, Brighton, United Kingdom. 2. Department of Microbiology and Immunology, Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran. 3. Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran. 4. Clinical Research Development Unit, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran. 5. Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Abstract
BACKGROUND: Changes in cell metabolism are a well-known feature of some cancers, and this may be involved in the etiology of tumor formation and progression, as well as tumor heterogeneity. These changes may affect fatty acid metabolism and glycolysis and are required to provide the increase in energy necessary for the high rate of proliferation of cancer cells. Gastrointestinal cancers remain a difficult-to-treat cancer, particularly as they are usually diagnosed at a late stage of disease and are associated with poor outcomes. SUMMARY: Recently, the changes in the metabolic pathways, including the expression of the rate-limiting enzymes involved, have been considered to be a potential target for therapy for gastrointestinal tumors. KEY MESSAGE: A combination of routine chemotherapy drugs with metabolic inhibitors may improve the effectiveness of treatment.
BACKGROUND: Changes in cell metabolism are a well-known feature of some cancers, and this may be involved in the etiology of tumor formation and progression, as well as tumor heterogeneity. These changes may affect fatty acid metabolism and glycolysis and are required to provide the increase in energy necessary for the high rate of proliferation of cancer cells. Gastrointestinal cancers remain a difficult-to-treat cancer, particularly as they are usually diagnosed at a late stage of disease and are associated with poor outcomes. SUMMARY: Recently, the changes in the metabolic pathways, including the expression of the rate-limiting enzymes involved, have been considered to be a potential target for therapy for gastrointestinal tumors. KEY MESSAGE: A combination of routine chemotherapy drugs with metabolic inhibitors may improve the effectiveness of treatment.
Authors: Sarah Brophy; Katherine M Sheehan; Deborah A McNamara; Joseph Deasy; David J Bouchier-Hayes; Elaine W Kay Journal: Int J Cancer Date: 2009-12-15 Impact factor: 7.396
Authors: Rafael Moreno-Sánchez; Alvaro Marín-Hernández; Juan Carlos Gallardo-Pérez; Héctor Quezada; Rusely Encalada; Sara Rodríguez-Enríquez; Emma Saavedra Journal: J Cell Biochem Date: 2012-05 Impact factor: 4.429